𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Intraperitoneal bleomycin. Pharmacokinetics and results of a phase II trial

✍ Scribed by Jacob D. Bitran

Publisher
John Wiley and Sons
Year
1985
Tongue
English
Weight
354 KB
Volume
56
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II evaluation of bleomycin. A Sout
Phase II evaluation of bleomycin. A Southwest Oncology Group study
✍ Charles D. Haas; Charles A. Coltman Jr.; Jeffrey A. Gottlieb; Arthur Haut; James πŸ“‚ Article πŸ“… 1976 πŸ› John Wiley and Sons 🌐 English βš– 369 KB πŸ‘ 2 views

Bleomycin given intravenously (i.v.) or intramuscularly (i.m.) in twice-weekly doses of 10 mg/mz was evaluated for efficacy and toxicity in 382 patients. Responses were observed in 11/27 Hodgkin's diseases, 10/30 lymphomas, 9/22 squamous cell cancers of ectodermal origin, 12/26 germinal cancers, and

Outpatient combination chemoimmunotherap
Outpatient combination chemoimmunotherapy for patients with metastatic melanoma : Results of a Phase I/II trial
✍ Mohammed Kashani-Sabet; Richard W. Sagebiel; Henry E. Collins; Alan B. Glassberg πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 75 KB πŸ‘ 2 views

## BACKGROUND. Few studies have examined the feasibility, safety, and efficacy of an outpatient biochemotherapy regimen of low dose, subcutaneously administered interleukin-2 (IL-2) for patients with metastatic (Stage IV) melanoma. ## METHODS. Nineteen patients were treated with intravenous cispl

Safety and efficacy of a novel hepatobil
Safety and efficacy of a novel hepatobiliary MR contrast agent, Gd-DTPA-DeA: Results of phase I and phase II clinical trials
✍ Akihiro Tanimoto; Masumi Kadoya; Yasutaka Kawamura; Ryohei Kuwatsuru; Takehiko G πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 536 KB

## Abstract ## Purpose To assess the safety, effective dose, and efficacy of a novel hepatobiliary MR contrast agent Gd‐DTPA‐DeA for imaging liver tumors, from the clinical phase I and phase II trials in Japan. ## Materials and Methods In a phase I trial, 33 healthy volunteers were intravenously

Evaluation of gadobenate dimeglumine in
Evaluation of gadobenate dimeglumine in hepatocellular carcinoma: Results from phase II and phase III clinical trials in Japan
✍ Akihiro Tanimoto; Ryohei Kuwatsuru; Masumi Kadoya; Kuni Ohtomo; Shinji Hirohashi πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 794 KB

To evaluate the clinical efficacy of gadobenate dimeglumine (Gd-BOPTA)-enhanced magnetic resonance imaging for hepatocellular carcinoma (HCC), we reviewed the results of clinical phase II and III trials in Japan. Gd-BOPTA was administered at a dose of 0.1 mmol/kg to 139 patients who were suspected t